Jupiter Endovascular

Jupiter Endovascular, Inc., a medical technology startup based in Menlo Park, California, is developing innovative solutions for catheter-based surgeries. The company's flagship technology, the Endoportal Control platform, aims to bring the precision and control of direct surgical access to endovascular procedures. This technology utilizes an endoportal device that navigates flexibly through the vasculature via percutaneous access. Once in position, the device can be fixed into a stable state, allowing for the delivery of interventional treatments with surgical-like precision from an endovascular access point. This approach is designed to overcome the technological constraints of traditional catheters that lose stability and control within the anatomy, potentially addressing significant unmet clinical needs in patients with diseases in complex cardiovascular anatomies, such as the pulmonary arteries.

In August 2024, Jupiter Endovascular exited stealth mode with USD 21 million in new financing. The company plans to use this funding to support an upcoming pivotal trial for pulmonary embolism and to develop additional clinical applications of its Endoportal Control technology. Jupiter Endovascular was spun out from Neptune Medical, which shifted its focus to gastrointestinal robotics. Coinciding with its exit from stealth mode, Jupiter Endovascular appointed Carl J. St. Bernard as its Chief Executive Officer. St. Bernard, an industry veteran with over 30 years of experience in the life sciences arena, joined the company from Alta Biomaterials.

Key customers and partnerships

Sonder Capital and Olympus Corporation of the Americas were significant participants in Jupiter Endovascular's funding round, which also included multiple strategic investors. Kate Garrett, managing partner at Sonder Capital, highlighted the potential of Jupiter Endovascular's approach to address unmet clinical needs in patients with diseases in complex cardiovascular anatomies.